will evaluate the efficacy and safety of Targeted Radionuclide Therapy with 177Lu-Edotreotide / Solucin® in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET).
Additional study information for patients provides an established supplement to the discussion with the doctor, which is appreciated by patients and relatives. For patient protection and to guarantee a high quality standard of this patient website the content is currently reviewed and released by an appropriate board.
The trial will be conducted worldwide in 11 countries at 33 sites and is now open for recruitment. Healthcare professionals who are interested in enrolling patients will find comprehensive background information on this site.